Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast - A comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours

Breast

Volumn 14, Issue 4, 2005, Pages 290-297

  Idvall, Ingrid ^a,b   Ringberg, Anita ^a   Anderson, Harald ^a   Åkerman, Måns ^a   Fernö, Mårten ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

Author keywords

Breast; Contralateral; DCIS; Ductal carcinoma in situ; Ipsilateral; Recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; CONTROLLED STUDY; CYTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; ORGAN PRESERVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SURGICAL TECHNIQUE;

EID: 23444461367     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.02.002     Document Type: Article

References (34)

1. F. Wärnberg J. Bergh M. Zack L. Holmberg Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: A population-based case-control study in Sweden Cancer Epidemiol Biomarkers Prev 10 2001 495-499
2. K.A. Skinner M.J. Silverstein The management of ductal carcinoma in situ of the breast Endocr Relat Cancer 8 2001 33-45
3. M.D. Lagios P.R. Westdahl F.R. Margolin M.R. Rose Relationship of the extent of non-invasive disease to the frequency of occult invasion, multicentricity, lymph node metastases and short-term treatment failures Cancer 50 1982 1309-1314
4. E.R. Fisher J. Dignam E. Tan-Chiu et al. Pathologic findings from the National Adjuvant Breast Project (NSABP) eight-year update of protocol B-17 Cancer 86 1999 429-438
5. B. Fisher J. Constantino C. Redmond et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer N Engl J Med 328 1993 1581-1586
6. N. Bijker J.L. Peterse L. Duchateau et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853 J Clin Oncol 19 2001 2263-2271
7. A. Ringberg I. Idvall M. Fernö et al. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast Eur J Surg Oncol 26 2000 444-451
8. N. Bijker J.L. Peterse L. Duchateau et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ Br J Cancer 84 2001 539-544
9. O.T. Lampejo D.M. Barnes P. Smith R.R. Millis Evaluation of infiltrating ductal carcinomas with a DCIS component: Correlation of the histologic type of the in situ component with grade of the infiltrating component Semin Diagn Pathol 11 1994 215-222
10. R.R. Millis D.M. Barnes O.T. Lampejo M.K. Egan P. Smith Tumour grade does not change between primary and recurrent mammary carcinoma Eur J Cancer 34 1998 548-553
11. G.F. Robbins J.W. Berg Bilateral primary breast cancer: A prospective clinicopathological study Cancer 17 1964 1501-1527
12. P.H. Leis Jr Managing the remaining breast Cancer 46 1980 1026-1030
13. P.L. Horn W.D. Thompson Risk of contralateral breast cancer. Associations with histologic, clinical and therapeutic factors Cancer 62 1988 412-424
14. L.A. Dawson E. Chow P.E. Goss Review. Evolving perspectives in contralateral breast cancer Eur J Cancer 34 1998 2000-2009
15. J. Kollias I.O. Ellis C.W. Elston R.W. Blamey Clinical and histological predictors of contralateral breast cancer Eur J Surg Oncol 25 1999 584-589
16. P.J. Dawson T. Maloney P. Gimotty P. Juneau H. Ownby S.R. Wolman Bilateral breast cancer: One disease or two? Breast Cancer Res Treat 19 1991 233-244
17. P. Broet A. de la Rochefordiere S.M. Scholl et al. Contralateral breast cancer: Metastasis or second primary cancer? Bull Cancer 83 1996 870-876
18. N. Pandis M.R. Teixeira A.M. Gerdes et al. Chromosome abnormalities in bilateral breast carcinomas. Cytogenetic evaluation of the clonal origin of multiple primary tumours Cancer 76 1995 250-258
19. B. Cutuli C. Cohen-Solal-le Nir B. de Lafontan et al. Breast conserving therapy for ductal carcinoma in situ of the breast: The French Cancer Center's experience Int J Radiat Oncol Biol Phys 53 2002 868-879
20. B.L. Webber H. Heise J.P. Neifeld J. Costa Risk of subsequent contralateral breast carcinoma in a population of patients with in-situ breast carcinoma Cancer 47 1981 2928-2932
21. A. Ringberg L. Anagnostaki H. Anderson I. Idvall M. Fernö Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics Eur J Cancer 37 2001 1514-1522
22. I. Idvall H. Anderson A. Ringberg M. Fernö Are cellular polarisation and mitotic frequency prognostic factors for local recurrence in patients with ductal carcinoma in situ of the breast? Eur J Cancer 39 2003 1704-1710
23. Consensus Conference on the classification of ductal carcinoma in situ. Hum Pathol 1997;28:1221-4.
24. C.W. Elston I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up Histopathology 19 1991 403-410
25. J.L. Fleiss Statistical methods for rates and proportions 2nd ed 1981 Wiley New York
26. D.F. Morrison Multivariate statistical methods 2nd ed 1976 McGraw-Hill New York
27. J.L. Hopper G.G. Giles G. Marr D.J. Venter J.E. Armes Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast Eur J Cancer 39 2003 622-630
28. F.M. Waldman S. DeVries K.L. Chew D.H. Moore II. K. Kerlikowske B.-M. Ljung Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences J Natl Cancer Inst 92 2000 313-320
29. D.M. Barnes J. Bartkova R.S. Camplejohn W.J. Gullik P.J. Smith R.R. Millis Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 28 1992 644-648
30. J.S. Ross J.A. Fletcher HER-2/neu (c-erb-B2) gene and protein in breast cancer Am J Clin Pathol 112 suppl 1 1999 S53-S67
31. S.J. Schnitt Breast cancer in the 21st century. Neu opportunities and neu challenges Mod Pathol 14 2001 213-218
32. J.D. Iglehart B.J. Kerns G. Huper J.R. Marks Maintenance of DNA-content and erbB-2 alterations in intraductal and invasive phases of mammary cancer Breast Cancer Res Treat 34 1995 252-263
33. H.C. Maguire Jr M.E. Hellman M.I. Greene I. Yeh Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast Pathobiology 60 1992 117-121
34. B. Fisher S. Land E. Mamounas J. Dignam E.R. Fisher N. Wolmark Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience Semin Oncol 28 2001 400-418